Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Outstanding (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Shares Outstanding data on record, last reported at $95.6 million in Q4 2025.

  • For Q4 2025, Shares Outstanding rose 2.85% year-over-year to $95.6 million; the TTM value through Dec 2025 reached $95.6 million, up 2.85%, while the annual FY2025 figure was $95.6 million, 2.85% up from the prior year.
  • Shares Outstanding reached $95.6 million in Q4 2025 per CRNX's latest filing, up from $94.5 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $95.6 million in Q4 2025 and bottomed at $4.8 million in Q1 2022.
  • Average Shares Outstanding over 5 years is $63.8 million, with a median of $60.7 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: crashed 85.52% in 2022, then surged 1029.5% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $47.6 million in 2021, then increased by 13.19% to $53.9 million in 2022, then increased by 26.54% to $68.2 million in 2023, then soared by 36.31% to $92.9 million in 2024, then rose by 2.85% to $95.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $95.6 million in Q4 2025, $94.5 million in Q3 2025, and $94.1 million in Q2 2025.